Microglia and Brain Macrophages As Drivers of Glioma Progression

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Dec 23

PMID 36555253

Authors

Yuqi Zheng

Manuel B Graeber

Affiliations

Soon will be listed here.

Abstract

Evidence is accumulating that the tumour microenvironment (TME) has a key role in the progression of gliomas. Non-neoplastic cells in addition to the tumour cells are therefore finding increasing attention. Microglia and other glioma-associated macrophages are at the centre of this interest especially in the context of therapeutic considerations. New ideas have emerged regarding the role of microglia and, more recently, blood-derived brain macrophages in glioblastoma (GBM) progression. We are now beginning to understand the mechanisms that allow malignant glioma cells to weaken microglia and brain macrophage defence mechanisms. Surface molecules and cytokines have a prominent role in microglia/macrophage-glioma cell interactions, and we discuss them in detail. The involvement of exosomes and microRNAs forms another focus of this review. In addition, certain microglia and glioma cell pathways deserve special attention. These "synergistic" (we suggest calling them "Janus") pathways are active in both glioma cells and microglia/macrophages where they act in concert supporting malignant glioma progression. Examples include CCN4 (WISP1)/Integrin α6β1/Akt and CHI3L1/PI3K/Akt/mTOR. They represent attractive therapeutic targets.

Citing Articles

Exosomes in the Chemoresistance of Glioma: Key Point in Chemoresistance.

Guo X, Piao H, Sui R J Cell Mol Med. 2025; 29(4):e70401.

PMID: 39950738 PMC: 11826829. DOI: 10.1111/jcmm.70401.

Divergent Crosstalk Between Microglia and T Cells in Brain Cancers: Implications for Novel Therapeutic Strategies.

Yi M, Lee J, Moon S, So E, Bang G, Moon K Biomedicines. 2025; 13(1).

PMID: 39857798 PMC: 11763300. DOI: 10.3390/biomedicines13010216.

Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.

Mwale P, Hsieh C, Yen T, Jan J, Taliyan R, Yang C Mol Neurodegener. 2025; 20(1):7.

PMID: 39827337 PMC: 11742494. DOI: 10.1186/s13024-025-00801-8.

New insights into the role of the CHI3L2 protein in invasive ductal breast carcinoma.

Rusak A, Katnik E, Gornicki T, Schmuttermaier C, Kujawa K, Piotrowska A Sci Rep. 2024; 14(1):28529.

PMID: 39557919 PMC: 11574116. DOI: 10.1038/s41598-024-77930-5.

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma.

Huang M, Zhang L, Wu Y, Zhou X, Wang Y, Zhang J Cent Eur J Immunol. 2024; 49(2):155-168.

PMID: 39381559 PMC: 11457564. DOI: 10.5114/ceji.2024.140651.

References

Franklin R, Liao W, Sarkar A, Kim M, Bivona M, Liu K . The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344(6186):921-5. PMC: 4204732. DOI: 10.1126/science.1252510. View

Li X, Guan J, Jiang Z, Cheng S, Hou W, Yao J . Microglial Exosome miR-7239-3p Promotes Glioma Progression by Regulating Circadian Genes. Neurosci Bull. 2021; 37(4):497-510. PMC: 8055789. DOI: 10.1007/s12264-020-00626-z. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Chen X, Zhang L, Zhang I, Liang J, Wang H, Ouyang M . RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res. 2014; 74(24):7285-7297. PMC: 4268204. DOI: 10.1158/0008-5472.CAN-14-1240. View

Ye X, Xu S, Xin Y, Yu S, Ping Y, Chen L . Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012; 189(1):444-53. DOI: 10.4049/jimmunol.1103248. View

Qian M, Wang S, Guo X, Wang J, Zhang Z, Qiu W . Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways. Oncogene. 2019; 39(2):428-442. DOI: 10.1038/s41388-019-0996-y. View

Zhao C, Zheng S, Yan Z, Deng Z, Wang R, Zhang B . CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2. Oncol Rep. 2020; 43(2):571-580. DOI: 10.3892/or.2019.7426. View

Zhang H, Zhang W, Sun X, Dang R, Zhou R, Bai H . Class A1 scavenger receptor modulates glioma progression by regulating M2-like tumor-associated macrophage polarization. Oncotarget. 2016; 7(31):50099-50116. PMC: 5226571. DOI: 10.18632/oncotarget.10318. View

Xuan W, Qu Q, Zheng B, Xiong S, Fan G . The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J Leukoc Biol. 2014; 97(1):61-9. DOI: 10.1189/jlb.1A0314-170R. View

10.

Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H . Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α. Nat Commun. 2018; 9(1):559. PMC: 5805734. DOI: 10.1038/s41467-018-03050-0. View

11.

Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T . Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015; 10(2):e0116644. PMC: 4320099. DOI: 10.1371/journal.pone.0116644. View

12.

Du Y, Yang Z, Sun Q, Lin M, Wang R, Peng Y . Engineered Microglia Potentiate the Action of Drugs against Glioma Through Extracellular Vesicles and Tunneling Nanotubes. Adv Healthc Mater. 2021; 10(9):e2002200. DOI: 10.1002/adhm.202002200. View

13.

Hasan M, Luo L, Ding D, Song S, Bhuiyan M, Liu R . Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. Theranostics. 2021; 11(3):1295-1309. PMC: 7738877. DOI: 10.7150/thno.50150. View

14.

Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F . Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996; 87(2):307-17. DOI: 10.1016/s0092-8674(00)81348-3. View

15.

Kaur N, Chettiar S, Rathod S, Rath P, Muzumdar D, Shaikh M . Wnt3a mediated activation of Wnt/β-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci. 2013; 54:44-57. DOI: 10.1016/j.mcn.2013.01.001. View

16.

Dong Z, Zhang G, Qu M, Gimple R, Wu Q, Qiu Z . Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock. Cancer Discov. 2019; 9(11):1556-1573. PMC: 6983300. DOI: 10.1158/2159-8290.CD-19-0215. View

17.

Lapteva N, Huang X . CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010; 10(5):725-33. DOI: 10.1517/14712591003657128. View

18.

Blockus H, Chedotal A . Slit-Robo signaling. Development. 2016; 143(17):3037-44. DOI: 10.1242/dev.132829. View

19.

Huang Y, Motta E, Nanvuma C, Kuhrt L, Yuan Y, Xia P . Microglia/macrophage-derived human CCL18 promotes glioma progression via CCR8-ACP5 axis analyzed in humanized slice model. Cell Rep. 2022; 39(2):110670. DOI: 10.1016/j.celrep.2022.110670. View

20.

Moon R, Kohn A, De Ferrari G, Kaykas A . WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701. DOI: 10.1038/nrg1427. View